Immunohistochemistry (IHC) of clinical samples revealed that YTHDF2 expression increases with tumor grade and correlates positively with PRMT6 expression (Supplementary Material 4: Fig. S4I-K). This evidence concerns the gene PRMT6 and neoplasm.